A recent study found that enoxaparin (Lovenox) can cause major bleeding in patients who have moderate renal impairment. The study, published in Archives of Internal Medicine, has reportedly prompted calls for updated dosing recommendations.
Enoxaparin is an anticoagulant drug marketed under the trade names Lovenox, Xaparin and Clexane.
Findings from the Enoxaparin Study
- The enoxaparin study involved 164 patients (105 with normal renal function, 59 with renal impairment.)
- Major bleeding occurred in 5.7% of normal renal groups vs. 22% of those with renal impairment.
- Study authors recommend doctors exercise caution in prescribing enoxaparin in patients with moderate renal impairment, especially in the “perioperative period.”
- They also recommend an “evidence-based update of current dosing recommendations for patients receiving any anticoagulant that is renally cleared.”
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or medical devices, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.